{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-038225","form_type":"8-K","ticker":"BLFS","cik":"0000834365","company_name":"BIOLIFE SOLUTIONS INC","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.125165+00:00","generated_at":"2026-06-08T08:14:38.111697+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BioLife Solutions Q3 revenue falls 18% YoY; net loss widens to $29.1M on $15.5M impairment","bullets":["Total revenue $33.3M, down 18% YoY; ex-COVID revenue down 10%.","GAAP net loss $29.1M ($0.67 EPS) vs $10.3M loss in Q3 2022; includes $15.5M non-cash impairment.","Biostorage and Services ex-COVID revenue grew 50% YoY; cell processing revenue down 26%.","Cash $42.2M at quarter end; raised $10.4M via share sale in October 2023.","FY2023 revenue guidance narrowed to low end of $144-158M; freezer divestiture expected in early 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-038225","json":"https://secwatch.observer/filing/0001628280-23-038225.json","markdown":"https://secwatch.observer/filing/0001628280-23-038225.md","text":"https://secwatch.observer/filing/0001628280-23-038225.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/834365/000162828023038225/0001628280-23-038225-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/834365/000162828023038225/blfs-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T08:14:38.111697+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"99ab3c335e87ec47010bf8aaa5d53ee98a36fdf8","claim":"BIOLIFE SOLUTIONS INC reported third quarter ended September 30, 2023 results: revenue $33.3 million, net income Net loss (GAAP) for the third quarter of 2023 was $29.1 million, EPS Loss per share (GAAP) for the third quarter of 2023 was $0.67. Guidance reaffirmed.","evidence_excerpt":"news release. 3303 Monte Villa Parkway, Suite 310 | Bothell, WA 98021 USA | 866.424.6543 phone | BioLifeSolutions.com REVENUE • Total revenue for the third quarter of 2023 was $33.3 million, a decrease of $7.4 million, or 18%, from $40.7 million for the third quarter of 2022. There was no COVID related revenue in the third quarter of 2023. Ex-COVID related revenue","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/834365/000162828023038225/0001628280-23-038225-index.htm","confidence":0.97,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$33.3 million"},{"label":"Net income","value":"Net loss (GAAP) for the third quarter of 2023 was $29.1 million"},{"label":"EPS","value":"Loss per share (GAAP) for the third quarter of 2023 was $0.67"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}